Performance of Finnish biobanks in nationwide pulmonary carcinoid tumour research

Show full item record



Vesterinen , T , Salmenkivi , K , Mustonen , H , Kuopio , T , Lappi-Blanco , E , Paavonen , T , Vainio , P , Knuuttila , A , Carpén , O , Haglund , C & Arola , J 2020 , ' Performance of Finnish biobanks in nationwide pulmonary carcinoid tumour research ' , Virchows Archiv , vol. 476 , no. 2 , pp. 273-283 .

Title: Performance of Finnish biobanks in nationwide pulmonary carcinoid tumour research
Author: Vesterinen, Tiina; Salmenkivi, Kaisa; Mustonen, Harri; Kuopio, Teijo; Lappi-Blanco, Elisa; Paavonen, Timo; Vainio, Paula; Knuuttila, Aija; Carpén, Olli; Haglund, Caj; Arola, Johanna
Contributor organization: HUSLAB
Institute for Molecular Medicine Finland
Department of Pathology
University of Helsinki
Helsinki Institute of Life Science HiLIFE
HUS Abdominal Center
Department of Surgery
Department of Medicine
Keuhkosairauksien yksikkö
HUS Heart and Lung Center
Precision Cancer Pathology
Olli Mikael Carpen / Principal Investigator
Research Program in Systems Oncology
Research Programs Unit
II kirurgian klinikka
CAN-PRO - Translational Cancer Medicine Program
Faculty of Medicine
Date: 2020-02
Language: eng
Number of pages: 11
Belongs to series: Virchows Archiv
ISSN: 1432-2307
Abstract: Finnish hospital-integrated biobanks administer millions of formalin-fixed paraffin-embedded tissue samples collected within the clinical diagnostics. According to the Finnish Biobank Act, these samples can be coupled with patients’ clinical follow-up data and the data retrieved from national health registries. We collected a nationwide pulmonary carcinoid tumour series from Finnish biobanks to study prognostic factors as well as to explore how the number of tumours found in the Finnish biobanks corresponds to the number of tumours registered by the Finnish Cancer Registry (FCR). Finnish biobanks identified 88% of the tumours registered by the FCR and were able to deliver 63%. The main reasons for lacking samples were paucity of resected primary tumour tissue, incompatible primary diagnosis, and the absence of tissue blocks in the archives. The main bottleneck in the sample application process was retrieving patient data. Altogether, we received 224 tumour samples with appropriate patient data and identified six prognostic factors for shorter disease-specific survival: age over 56 years at the time of diagnosis, tumour size over 2.5 cm, atypical histology, Ki-67 proliferation index higher than 2.5%, hilar/mediastinal lymph node involvement at the time of diagnosis, and the presence of metastatic disease. In conclusion, the Finnish biobank infrastructure offers excellent opportunities for tissue-based research. However, to be able to develop the biobank operations further, involving more medical knowledge in the sample and data acquisition process is a necessity. Also, when working with tissue samples collected over decades, histological expertise is essential for re-evaluation and re-classification of the samples.
Subject: 3122 Cancers
Rare cancer
Pulmonary carcinoid
3111 Biomedicine
Peer reviewed: Yes
Rights: cc_by
Usage restriction: openAccess
Self-archived version: publishedVersion

Files in this item

Total number of downloads: Loading...

Files Size Format View
Vesterinen2020_ ... nceOfFinnishBiobanksIn.pdf 932.7Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record